Illinois AG Kwame Raoul reached an $8.25 million settlement with Mylan Inc. resolving allegations that the company used anticompetitive tactics to monopolize the epinephrine auto-injector market and overcharge Illinois Medicaid and employee health benefits programs for EpiPens. According to the AG’s office, Mylan allegedly raised prices, delayed generic competition, forced consumers to buy two-packs instead…

Read More

Maryland AG Anthony Brown and North Carolina AG Jeff Jackson announced separate settlements with Mylan resolving allegations that the company used anticompetitive tactics to maintain EpiPen’s market dominance and drive up prices for the life-saving allergy medication. According to the AGs’ offices, Mylan allegedly suppressed generic competition through exclusionary contracts with pharmacy benefit managers, delayed…

Read More

Louisiana AG Liz Murrill reached a $45 million settlement with CVS Health Corp. and its pharmacy benefit manager (PBM) subsidiary to resolve three lawsuits alleging deceptive and anti-competitive practices that allegedly violated the Louisiana Unfair Trade Practices Act. According to the AG’s office, the settlement resolves allegations that CVS improperly used customer information to conduct…

Read More

The FTC reached a settlement with Express Scripts, Inc. and its affiliates (collectively “Express Scripts”) to resolve an administrative lawsuit alleging the pharmacy benefit manager violated Section 5 of the FTC Act by artificially inflating insulin prices.

Read More

Iowa AG Brenna Bird filed a lawsuit against multiple pharmacy benefit managers (PBMs) and insulin manufacturers, alleging the companies violated Iowa’s Consumer Fraud Act by artificially inflating diabetes drug prices for Iowa consumers. According to the petition, the PBMs and manufacturers allegedly engaged in an unlawful pricing scheme that substantially increased the price of insulin…

Read More